Lunatus

What Lunatus does

Lunatus is a Dubai-headquartered pharmaceutical commercialization and distribution partner that has operated as a bridge between international healthcare companies and the Arabian Gulf and Middle East markets since 2003. The company serves as a turnkey commercial partner for global pharmaceutical manufacturers seeking to enter or expand in the GCC region, providing integrated services spanning regulatory affairs, marketing, sales, distribution, and supply chain management. Its enterprise go-to-market relies on field sales teams positioned across GCC countries, executing specialist detailing, pharmacy sales, and direct-to-consumer channels, supported by data-driven sales activity optimization.

The company's product portfolio includes over 300 product lines across 16 therapeutic categories — Cardiovascular, Dermatology, ENT, Gastroenterology, Gynecology, Infectious Diseases, Internal Medicine, Neurology, Oncology, Ophthalmology, Orthopaedic, Pain Management, Pediatrics, Psychiatric, Vascular, and Weight Loss — distributed on behalf of more than 40 global partner companies. Specific disclosed products include prescription pharmaceuticals such as Xenical (Orlistat 120 mg) and medical devices such as the Allurion Gastric Balloon System. Underlying technology is not publicly disclosed; the company is positioned as a services and commercialization platform rather than a technology product company, with no public API, proprietary software platform, or AI capabilities articulated in available materials.

Lunatus earns revenue on a transaction-fee basis, capturing margins from end-to-end commercialization of partner products across the GCC. Pricing is negotiated case-by-case rather than via standardized public rates. The company is privately held; in 2022, Japanese conglomerate Marubeni Corporation made a strategic investment and share acquisition, providing corporate backing. Subsequent exclusive agency agreements with partners including IBSA Group, LENZ Therapeutics, ORTHOREBIRTH, KYORIN, and Hartington Pharmaceutical indicate an accelerating partnership pipeline into 2025-2026. No public revenue, headcount, or AI/technology metrics are disclosed, and no public listing exists.

Name

Lunatus

Legal name

Lunatus

Website

https://lunatus.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Lunatus is a Dubai-based pharmaceutical commercialization partner that connects 40+ international healthcare companies with Middle Eastern markets, offering turnkey regulatory, marketing, sales, distribution, and supply chain services across the GCC region since 2003.

Ownership category

akta.pro rank

Headquarters

HQ city

Dubai

HQ country

United Arab Emirates

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Distribution and Commercialization: Lunatus generates revenue by providing turnkey solutions for international pharmaceutical companies entering the Middle Eastern market. As a commercial partner, they handle regulatory affairs, marketing, sales, distribution, and supply chain management, earning margins on product commercialization across the Arabian Gulf and Middle East region.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Lunatus provides turnkey pharmaceutical and healthcare commercialization services for international companies entering the Middle East. The company handles regulatory affairs, marketing, sales, distribution, and supply chain management, representing over 40 global partners across 300+ product lines spanning 16 therapeutic categories.

Product overview

Lunatus operates as a full-service healthcare partner in the Middle East, connecting global pharmaceutical and healthcare companies with Arabian Gulf markets. The company offers 300+ product lines across 16 therapeutic categories including Cardiovascular, Dermatology, ENT, Gastroenterology, Gynecology, Infectious Diseases, Internal Medicine, Neurology, Oncology, Ophthalmology, Orthopaedic, Pain Management, Pediatrics, Psychiatric, Vascular, and Weight Loss. Lunatus provides integrated turnkey solutions encompassing Regulatory Affairs, Marketing, Sales, Distribution, and Supply Chain Management. The product portfolio includes pharmaceutical medications like Xenical (Orlistat) and medical devices such as the Allurion Gastric Balloon System for weight management.

Differentiator

Problem solved

Functional benefit

Products and services

• Xenical (Orlistat) 120 mg Capsules Prescription weight loss medication containing 120 mg Orlistat, a lipase inhibitor that reduces fat absorption in the digestive system, used in conjunction with a reduced-calorie diet. Distributed by Lunatus for the Middle East market.
• Allurion Gastric Balloon System Non-surgical, minimally invasive gastric balloon system designed for weight loss, placed in the stomach through a non-surgical procedure to promote portion control. Distributed by Lunatus for the Middle East market.
• GPS Cancer Advanced Molecular Analysis Molecular diagnostic testing service for personalized cancer treatment decisions, distributed exclusively by Lunatus in the GCC and Lebanon following the December 2016 partnership with NantHealth.
• Pharmaceutical Regulatory Affairs Services End-to-end regulatory affairs and compliance services for pharmaceutical and healthcare companies entering the Middle East, including registration management with in-house legal counsel ensuring compliance with local and international laws.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered core and major.

• ORTHOREBIRTHcoreChannel Partner/ Reseller/ Distributor · 1 February 2026Exclusive agency agreement for ReBOSSIS across the Middle East, announced February 26, 2026.
• KYORINcoreChannel Partner/ Reseller/ Distributor · 1 January 2026Exclusive agency agreement for Lasvic tablets across the Middle East, announced January 6, 2026.
• Hartington PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 1 January 2026Exclusive agency agreement for NASODREN nasal spray across the Middle East, announced January 2026.
• LENZ TherapeuticscoreChannel Partner/ Reseller/ Distributor · 1 January 2026Exclusive commercialization partnership for VIZZ in the Middle East, announced January 5, 2026.
• AFYX Therapeutics A/ScoreChannel Partner/ Reseller/ Distributor · 1 May 2025Distribution and sales collaboration announced May 2, 2025.
• IBSA GroupmajorStrategic or Co-development Partner · 1 March 2025In partnership with Lunatus, IBSA Group strengthens its presence in the Middle East in the osteoarticular area, announced March 18, 2025.
• BioQ PharmacoreStrategic or Co-development Partner · 1 April 2017BioQ Pharma and Lunatus expanded their commercial agreement to include a third ready-to-use infusible pharmaceutical product. The agreement covers ropivacaine and propofol infusion pharmaceutical products in Saudi Arabia, UAE, Qatar, and Kuwait.
• NantHealthcoreStrategic or Co-development Partner · 1 December 2016In December 2016, Lunatus entered an exclusive reseller agreement with NantHealth for GPS Cancer Advanced Molecular Analysis. This partnership enables oncologists in UAE, Saudi Arabia, Kuwait, Oman, Bahrain, Qatar, and Lebanon to access molecular tests for personalized cancer treatment decisions.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Ali Abdulwahab Al Mutawa (AAW) - Healthcare Division: Kuwaiti conglomerate with a healthcare and pharmaceutical distribution arm serving GCC markets. Comparable as a regional distribution partner for international pharma brands entering Kuwait and neighboring GCC countries.

Direct peers

• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corp.): Saudi Arabia-listed pharmaceutical manufacturer and distributor with broad GCC distribution network. Comparable as a major regional pharma player covering similar therapeutic categories across Saudi Arabia and broader GCC markets.
• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer and distributor with broad GCC presence across multiple therapeutic categories. Directly comparable as a regional pharma commercialization and distribution player operating in Lunatus's core geographies.
• Tabuk Pharmaceuticals: Saudi Arabia-based pharmaceutical company with strong GCC distribution and commercialization capabilities, including partnerships with global pharma firms for MENA market entry — a similar business model to Lunatus's commercialization partner offering.
• Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical company with deep MENA manufacturing and commercialization footprint. Highly comparable as a regional pharma partner that manufactures, distributes, and licenses across the same GCC geographies and therapeutic categories as Lunatus.
• Pharmax Pharmaceuticals: UAE-based pharmaceutical company focused on manufacturing and distributing branded generics across the MENA region. Comparable as a regional pharma distributor operating across overlapping therapeutic categories and GCC geographies.

Broad incumbents

• DKSH (Healthcare): Swiss-headquartered market expansion services group with a major healthcare unit providing distribution, regulatory, and commercialization services across Asia and select MENA markets. Comparable as a full-service pharma market-entry partner.
• McKesson Corporation: Global pharmaceutical distribution and healthcare services leader with operations in multiple regions. Relevant as a potential competitor and benchmark for the wholesale pharma distribution services that anchor Lunatus's business.
• Zuellig Pharma: Asia-Pacific headquartered healthcare distribution and commercialization services group with growing MENA presence. Comparable as a turnkey pharma commercialization partner covering regulatory, distribution, and sales services across emerging markets.
• Aspen Pharmacare: South African-headquartered global specialty pharma company with established MENA commercial presence. Comparable as an international pharma partner using regional distribution intermediaries for MENA market access.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lunatus

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lunatus